Document Detail


Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.
MedLine Citation:
PMID:  15222408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitor use is presumed to be contraindicated in patients with aortic stenosis (AS). We determined the hemodynamic effects of ACE inhibitors in patients with mild to moderate aortic stenosis (AS) and preserved left ventricular function. METHODS: Thirteen elderly patients (mean [SD] age = 65 [17] years), with mild to moderate AS (aortic jet velocity 2.5-4.0 m/s), normal left ventricular and renal function, and no clinical coronary artery disease, were enrolled in a single-center, open-label trial comparing the hemodynamic effects at baseline and following titration of ramipril to a maximum dose of 7.5 mg twice daily. Patients were identified from echocardiography laboratory logs. Despite a presumed contraindication to ACE inhibitor use in AS patients, 30% (71 of 235) of patients otherwise meeting inclusion or exclusion criteria were excluded owing to current ACE inhibitor use. Patients were monitored with weekly clinic visits, biweekly laboratory tests, and monthly echocardiograms. RESULTS: There were no significant changes from baseline to week 8 in echocardiographic parameters, including mean (SD) aortic jet velocity [2.9 (0.4) vs 2.9 (0.4) m/s], calculated aortic transvalvular gradient [18 (6) vs 18 (6) mm Hg], or cardiac output [5.5 (1.2) vs 6.0 (2.1) L/min], or significant changes in blood pressure or heart rate. Early discontinuations were for asymptomatic low blood pressure (one patient) or a reversible creatinine increase of 0.3 mg/dL (one patient). CONCLUSIONS: Short-term treatment with up to 7.5 mg twice daily of ramipril was well tolerated in patients with mild to moderate AS and preserved left ventricular function. A surprisingly high proportion of patients with documented AS were already receiving ACE inhibitors.
Authors:
Kevin D O'Brien; Xue-Qiao Zhao; David M Shavelle; Michael T Caulfield; Rebecca A Letterer; Samir R Kapadia; Jeffrey L Probstfield; Catherine M Otto
Related Documents :
3158498 - Ultrasound characteristics of myocardial hypertrophy in patients affected by hypertroph...
6822098 - Cardiac abnormalities in mixed connective tissue disease.
20159638 - Usefulness of echocardiographic dyssynchrony in patients with borderline qrs duration t...
2562818 - Prevalence of cardiac abnormalities in human immunodeficiency virus infection.
15924598 - Is mild asthma really 'mild'?
21208438 - Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-n...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of investigative medicine : the official publication of the American Federation for Clinical Research     Volume:  52     ISSN:  1081-5589     ISO Abbreviation:  J. Investig. Med.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-06-29     Completed Date:  2004-07-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9501229     Medline TA:  J Investig Med     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  185-91     Citation Subset:  IM    
Affiliation:
Division of Cardiology, University of Washington, Seattle, WA 98195-6422, USA. cardiac@u.washington.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / contraindications,  pharmacology,  therapeutic use*
Aortic Valve Stenosis / complications,  drug therapy*,  physiopathology
Female
Hemodynamics / drug effects*
Humans
Male
Middle Aged
Ramipril / contraindications,  pharmacology,  therapeutic use*
Treatment Outcome
Ventricular Function, Left / physiology*
Grant Support
ID/Acronym/Agency:
M01-RR-00037/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density ...
Next Document:  Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults.